Skip to main content Back to Top
Advertisement

10/12/2020

Ethambutol Tablets

Products Affected - Description

    • Myambutol tablet, X-Gen, 400 mg, 100 count, NDC 68850-0012-02
    • Myambutol tablet, X-Gen, 400 mg, 100 count, NDC 68850-0012-01
    • Ethambutol tablet, Lupin, 400 mg, 100 count, NDC 68180-0281-01
    • Ethambutol tablet, STI Pharma, 100 mg, 100 count, NDC 54879-0001-01
    • Ethambutol tablet, STI Pharma, 400 mg, 100 count, NDC 54879-0002-01
    • Ethambutol tablet, Teva, 400 mg, 100 count, NDC 00555-0923-02 - discontinued

Reason for the Shortage

    • Lupin did not provide a reason for the shortage.
    • STI Pharma did not provide a reason for the shortage.
    • Teva discontinued ethambutol tablets in September 2020.
    • X-Gen did not provide a reason for the shortage.

Available Products

    • Ethambutol tablet, Lupin, 100 mg, 100 count, NDC 68180-0280-01

Estimated Resupply Dates

    • Lupin has ethambutol 400 mg tablets on back order and the company cannot estimate a release date.
    • STI Pharma has ethambutol 100 mg and 400 mg tablets on intermittent back order and the company is releasing supplies as they become available.
    • X-Gen has Myambutol tablets on back order and the company cannot estimate a release date.

Updated

Updated October 12, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created June 10, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.